Abbott Laboratories (ABT Stock) Acquires Bigfoot Biomedical

• Abbott Laboratories has acquired Bigfoot Biomedical.
• The ABT stock is down by 17% during the downtrend momentum since July. 
• It has declined by 0.73% in the last 24 hours and is trading at $95.53. 

The Abbott Laboratories (ABT) stock has witnessed solid bearish dominance since July 24, 2023. Hence, the downtrend trendline has shattered the price below $100. It has slid 0.73% in the past 24 hours and is trading at $95.53. The ABT share price has experienced high volatility while staying between $120 and $90.

The ABT stock was hovering below the significant moving average, indicating the bearish sentiment in the market. The stock is trading below the 20, 50, 100, and 200-day EMAs. It reflects the negative outlook due to the continued decrease in the price action. 

The year-to-date and the rest of the short-term returns show contradicting results that indicate the ABT stock suffered heavily in the current fiscal year. As statistics reveal, the year-to-date and three-month returns are -13.56% and -10.74%, respectively. Those returns have also impacted the market capitalization of Abbott Laboratories, which is $165.77 Billion.

Abbott Laboratories Acquires Bigfoot Biomedical

Abbott Laboratories completed the acquisition of Bigfoot Biomedical on September 22, 2023. Bigfoot Biomedical is the leader in developing intelligent insulin management systems for the diabetic patient. The transaction expanded the company’s presence in diabetic care, building on its FreeStyle Libre portfolio of its world-leading continuous glucose monitoring technology.

Q2-2023 Consensus Of Abbott Laboratories

Abbott Laboratories (NYSE: ABT) announced its pragmatic 2nd quarter financial report on July 20, 2023. Despite the losses of the current fiscal year, the ABT stock still managed to surpass the Q2 consensus estimates, whereas the reported earnings of 1.08 per share outclassed the estimated 1.05 EPS.   

Moreover, the 2nd quarter revenue revealed a growth of 2.75%, whereas the reported revenue of $9.98 Billion surpassed the estimated 9.71 Billion. The company blamed the decreased sales of its COVID testing kits as COVID-19 emerged as an endemic.

Will ABT Stock Fall Towards $90 Mark?

The market structure displays bearish dominance on the daily chats while bulls are still struggling to gain momentum. The Relative Strength Index (RSI) has slipped from the 50-neutral mark since August 1, 2023. It is currently at 22.07, which indicates solid weakness and the price is in an oversold zone.

The CMF was hovering below the 0.00 mark on August 9, 2023. It is at -0.41, denoting the massive presence of sellers in the market. 

Conclusion 

The recent quarterly report has impacted the downfall of the ABT stock. At the same time, the price witnessed a downtrend momentum while forming lower lows. The technical and analyst ratings favor the selling side, but traders should be careful about the $100 mark.

Technical Levels 

Major resistance: $115.83 and $112.95

Major support: $96.39 and $94.76

Disclaimer

The views and opinions stated by the author, or any people named in this article, are for informational purposes only. They do not establish financial, investment, or other advice. Investing in or trading crypto assets comes with a risk of financial loss.